secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2026-06-11T20:15:15+00:00
Accession:  0001193125-26-267563
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

All four proposals approved at Cardiff Oncology 2026 annual meeting, including equity plan increase to 15.15M shares
--------------------------------------------------------------------------------

- All six director nominees elected; broker non-votes of ~22.3M shares for each.
- Ratification of BDO USA as independent auditor for FY2026: 40.24M for, 1.07M against.
- Amendment to 2021 Equity Incentive Plan increasing authorized shares to 15.15M approved: 10.74M for, 8.06M against.
- Advisory say-on-pay vote on named executive officer compensation approved: 17.12M for, 1.77M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526267563/0001193125-26-267563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526267563/crdf-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-267563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer